ArticleCarcinogenesis2008
Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer.
Article in Carcinogenesis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- The emerging potentials of lncRNA DRAIC in human cancers.Frontiers in oncology · 2022Review
- Decreased expression of RASSF10 correlates with poor prognosis in patients with colorectal cancer.Medicine · 2017Article
- CpG island methylator phenotype in adenocarcinomas from the digestive tract: Methods, conclusions, and controversies.World journal of gastrointestinal oncology · 2017Article
- Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- Article
- Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma.Clinical & experimental metastasis · 2016Article
- Article
- Identification of differentially methylated genes in the malignant transformation of ovarian endometriosis.Journal of ovarian research · 2014Article
- Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer.Medical oncology (Northwood, London, England) · 2012Article
- Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice.The EMBO journal · 2012Article
- Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients.Experimental and therapeutic medicine · 2012Article
- Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy.Molecular biology international · 2012Article
- Prognostic significance of aberrant gene methylation in gastric cancer.American journal of cancer research · 2012Article
- Integrative epigenomic and genomic analysis of malignant pheochromocytoma.Experimental & molecular medicine · 2010Article
- DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae.Cancer science · 2010Article
- The Ras effector RASSF2 controls the PAR-4 tumor suppressor.Molecular and cellular biology · 2010Article
- Article
- Megaoesophagus in Rassf1a-null mice.International journal of experimental pathology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer cells often show altered Ras signaling, though the underlying molecular mechanism is not fully understood. We examined the expression profile of eight ras-association domain family (RASSF) genes plus MST1/2 and found that RASSF2A is the most frequently downregulated in gastric cancer. RASSF2A was completely silenced in 6 of 10 gastric cancer cell lines as a result of promoter methylation, and expression was restored by treating the cells with 5-aza-2'-deoxycytidine. Introduction of RASSF2A into non-expressing cell lines suppressed colony formation and induced apoptosis. These effects were associated with the cytoplasmic localization of RASSF2A and morphological changes to the cells. Complementary DNA microarray analysis revealed that RASSF2A suppresses the expression of inflammatory cytokines, which may in turn suppress angiogenesis and invasion. In primary gastric cancers, aberrant methylation of RASSF2A was detected in 23 of 78 (29.5%) cases, and methylation correlated significantly with an absence of the lymphatic invasion, absence of venous invasion, absence of lymph node metastasis, less advanced stages, Epstein-Barr virus, absence of p53 mutations and the presence of the CpG island methylator phenotype-high. These results suggest that epigenetic inactivation of RASSF2A is required for tumorigenesis in a subset of gastric cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.